Colony stimulating factors: G-CSFs--filgrastim (Neupogen) and lenograstim (Granocyte).
The introduction of leucocyte growth factors produced by DNA biosynthetic technology has had a major impact on survival in patients with compromised immunity. Such agents have maximized the benefits of treatment with drugs which are otherwise potentially toxic to the bone marrow.
MacConnachie
A M
AM
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000998:Antiviral Agents / Q000009:adverse effects; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000188:drug therapy; D000069585:Filgrastim; D015774:Ganciclovir / Q000009:adverse effects; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects* / Q000276:immunology; D000078224:Lenograstim; D009369:Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim; D015774:Ganciclovir; D000069585:Filgrastim